Introduction: Every year in Russia, more than 200 thousand whole body PET/CT are performed for various diseases in patients without clinical and laboratory manifestations of chronic kidney disease (CKD). However, only the "area of interest" of the attending physician is analyzed, while the rest of the organs or rather their metabolic activity is neglected during the standard procedure of this contemporary and high-tech research method.

Aim: To perform a retrospective study of whole-body PET/CT as a tool for prophylactic clinical examination of the population in order to identify subclinical manifestations of chronic kidney disease MATERIALS AND METHODS: The results of whole-body PET/CT with 11C-choline were retrospectively analyzed for the detection of CKD in 100 patients of the Tyumen region who underwent a study for various indications outside the genitourinary system without history, clinical and laboratory manifestations of CKD.

Results: According to the results, 22% of patients had different manifestations of 11C-choline hypometabolism, indicating a decrease in the viability of the parenchyma. In 14% of patients, there was a local decrease in the uptake of 11C-choline without CT-signs of kidneys damage, and in 8% of cases there was a total decrease in their metabolism, coinciding with X-ray signs of renal scarring.

Conclusions: The possibility of early molecular study of nephropathy can be used for wider retrospective PET/CT clinical examination as one of the highly effective methods for detecting CKD, which needs further research.

Download full-text PDF

Source

Publication Analysis

Top Keywords

whole-body pet/ct
12
clinical examination
12
manifestations chronic
12
chronic kidney
12
kidney disease
12
pet/ct tool
8
examination population
8
population order
8
order identify
8
identify subclinical
8

Similar Publications

[A comparative study on the diagnostic value of F-PSMA PET/CT PRIMARY score and PSMA expression score for clinically significant prostate cancer].

Zhonghua Yi Xue Za Zhi

January 2025

Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing100730, China.

To compare the diagnostic value of fluorine 18-labelled prostate-specific membrane antigen (PSMA) PET/CT PRIMARY score and PSMA expression score for clinically significant prostate cancer (csPCa). The data of 70 patients with prostate cancer who underwent radical prostatectomy at Beijing Hospital from February 1, 2019 to February 29, 2024 were retrospectively analyzed. All patients underwent whole body F-PSMA PET/CT examination before surgery and pathological large sections of prostate specimens were made after surgery.

View Article and Find Full Text PDF

The superiority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) over conventional staging methods such as computed tomography (CT) and bone scintigraphy has now been demonstrated for almost all clinical stages of prostate cancer. In primary diagnostics, PSMA-PET/CT is therefore the new standard for risk-adapted whole-body staging. At the same time, PSMA-PET/CT provides a new risk-based classification for predicting overall survival across all early and late stages of the disease.

View Article and Find Full Text PDF

Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with longer half-lives, in clinical imaging trials. Procedures have been developed for quantitative PET and SPECT image calibration for use in clinical trials. The protocol uses a 3-step approach: check quantitative accuracy with a previously calibrated radionuclide in a simple geometry, check the novel trial radionuclide in the same geometry, and check the novel radionuclide in a more challenging, complex geometry (the National Electrical Manufacturers Association [NEMA] NU-2 International Electrotechnical Commission [IEC] image-quality phantom).

View Article and Find Full Text PDF

Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).

View Article and Find Full Text PDF

Integrin antagonist complex (IAC), a novel αvβ3 integrin antagonist peptidomimetic, has emerged as a promising agent for molecular imaging of tumor angiogenesis. This study evaluates the biodistribution and clinical efficacy of [Ga]Ga-DOTAGA-IAC PET/CT in detecting radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), comparing its diagnostic performance with [F]F-FDG PET/CT. In this prospective pilot study, RAIR-DTC patients underwent whole-body imaging with [F] F-FDG PET/CT, followed by [Ga]Ga-DOTAGA-IAC PET/CT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!